combination glp-1 and sglt2 Receptor Agonist Therapy With Without Inhibitors in Patients With Type 2 Diabetes SGLT2i and GLP-1 RA therapy

At 3 months, the Nu+Ex group showed significant improvements in gait speed, 5 sit-to-stand performance, SPPB scores, depressive symptoms, perceived health, fat-free mass, and appendicular muscle mass

Optimal fermentation conditions for enhanced glutathione production by Saccharomyces cerevisiae FF-8

This newly published research, Population Pharmacokinetic Modeling and Exposure Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies in CPT: Pharmacometrics & Systems Pharmacology (PSP), highlights how population pharmacokinetic modeling and exposure response analyses were used to characterize nemtabrutinib exposure and evaluate key efficacy and safety relationships in patients with hematologic malignancies

The entire particle size of this MFG is anywhere between .1 - .15 microns